Sangamo BioSciences (NASDAQ: SGMO) is a publicly held biotechnology company, focused on the research and development of novel transcription factors for the regulation of genes.
Edward Lanphier, President and CEO of Sangamo Biosciences, enlisted Equistone Partners to assist in the lease evaluation of a Sangamo laboratory facility located within the Wareham Properties portfolio in Richmond, California. Edward's strong inclination was to remain within the current facility, and renew the existing lease. The experiments conducted within Sangamo's molecular biology laboratory could not afford disruption, making a location move a less than desirable option.
Equistone Partners evaluated the client's needs and financial requirements for a new lease. By leveraging the market and running a comprehensive strategy, we achieved favorable terms for Sangamo. Through an exclusive engagement agreement, we insulated Sangamo from the negotiation process and interfaced with Wareham Properties on Sangamo’s behalf. As a result of our efforts, Sangamo was able to significantly reduce occupancy costs, save valuable time and resources, and preserve the goodwill and support of their landlord, Wareham Properties.
We saved Sangamo $1,000,000 over the term of the new lease with Wareham Properties.
"You coordinated the entire process, keeping us in the driver’s seat from a negotiation stand point, and properly informed throughout. You were always considerate of our time, and represented us professionally. I am convinced that without your involvement, we would not have reached as favorable an outcome. I would be happy to work with you again in the future and strongly recommend your services to anyone."
Senior Director, Finance
Sangamo BioSciences, Inc.
(SGMO : NASDAQ)